NeuroSense Therapeutics Ltd. (NRSN)
NRSN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NRSN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2021 |
| SEC CIK | 0001875091 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern." | 20-F 2026-03-31 |
| Cash and burn | $166K cash; operating cash flow -$1.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | 1,627,859 (2025-12-31); 23,228,941 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-09-14 | Source 2026-09-14 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-01-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Somekh Chaikin, Tel Aviv, Israel | PCAOB Form AP 2026-05-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $200K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$11.1M | -$7.7M | $166K | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2024 2024-12-31 | Not filed | -$10.2M | -$10.1M | $3.4M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2023 2023-12-31 | Not filed | -$10.1M | -$8.4M | $2.6M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2022 2022-12-31 | Not filed | -$10.5M | -$7.6M | $3.5M | No debt tags | Needs four quarters | 20-F 2025-04-07 |
| FY 2021 2021-12-31 | Not filed | -$4.0M | -$1.5M | $11.1M | No debt tags | Needs four quarters | 20-F 2024-04-04 |
| FY 2020 2020-12-31 | Not filed | -$2.8M | -$695K | $699K | No debt tags | Needs four quarters | 20-F 2023-03-22 |
| FY 2019 2019-12-31 | Not filed | -$1.2M | -$582K | $895K | No debt tags | Needs four quarters | 20-F 2022-04-14 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-01-29 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-31 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-02 |
Source: SEC EDGAR submissions feed, 314 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.6% |
| 1 month | -51.6% |
| 3 months | -80.9% |
| Year to date | -89.0% |
| 1 year | -90.8% |
| From 52-week high | -93.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| NRSNW | NeuroSense Therapeutics Ltd. Warrant | $0.0055 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| PPBT | Purple Biotech Ltd. | $1.68 | +3.70% | $2.7M |
| MDCX | Medicus Pharma Ltd. Common Stock | $1.69 | -13.33% | $3.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier